|Bid||1.0700 x 800|
|Ask||1.1000 x 29200|
|Day's Range||1.0500 - 1.1300|
|52 Week Range||0.9400 - 3.0400|
|Beta (3Y Monthly)||2.19|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 9, 2018 - Aug 10, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.00|
MannKind Corp (MNKD) reported financial results for their second quarter ending June 30th and provided a business update. Both gross and net product sales set new records, as did product margin. As a reminder, Afrezza is sold in 4-,8- and 12-unit cartridges.
2Q 2019 Total Revenues of $15.0 million; +285% vs. 2Q 2018 º 2Q 2019 Afrezza Net Revenue was $6.1 million; +62% vs. 2Q 2018 º 2Q 2019 Collaboration and Services Revenue was.
WESTLAKE VILLAGE, Calif., Aug. 05, 2019 -- MannKind Corporation (NASDAQ: MNKD) and One Drop today announced that they have signed a collaborative agreement that is intended to.
MannKind Corporation (MNKD) will release its 2019 second quarter and year-to-date financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, August 7, 2019. MannKind Corporation (MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut.
MannKind Corporation (MNKD) announced today that the Afrezza® safety and pharmacokinetics study in pediatric patients is now enrolling children 4-7 years of age (Cohort 3) and nearing completion for Cohort 2 (8-12 years of age). An interim review of data from individuals participating in the second cohort shows that the single‑dose pharmacokinetic profile of insulin levels for this age group is consistent with the pattern seen in adults. In addition, dosing over one month demonstrated a safety profile that was also consistent with that observed in adults. As a result of these findings, MannKind and the study investigators are proceeding with enrollment of the third cohort of subjects.
WESTLAKE VILLAGE, Calif., July 18, 2019 -- MannKind Corporation (NASDAQ: MNKD) today announced the repayment of outstanding debt by an aggregate amount of approximately $4.0.
WESTLAKE VILLAGE, Calif., July 15, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, today announced that it has partnered with GoodRx to help raise awareness on ways patients can save money on their mealtime insulin.
MannKind Corporation (MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced that it has completed construction of a new high-potency manufacturing suite in its Danbury Connecticut facility. This expansion provides the Company with the capability to produce dry powder formulations of highly potent active ingredients, such as epinephrine, on a commercial scale, in alignment with MannKind's strategic partnerships. The new suite will house bulk powder formulation and fill/pack operations for high-potency powders and adds to MannKind's extensive commercial manufacturing capability, which includes inhalation devices, large-scale compounding, particle formation, tangential flow filtration, cryogranulation, and high capacity (300 kg/day) lyophilization.
If you want to know who really controls MannKind Corporation (NASDAQ:MNKD), then you'll have to look at the makeup of...
New data from three different studies of Afrezza was announced at the American Diabetes Association’s 79th Scientific Sessions (June 7 – 11) in San Francisco. This includes safety and PK data from MannKind’s (MNKD) ongoing pediatric study. This pediatric data, which comes from the first of three age-based patient cohorts is particularly insightful as it provides one of the initial meaningful glimpses of utility of Afrezza in younger populations.
WESTLAKE VILLAGE, Calif., June 12, 2019 -- MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for.
MannKind Corporation (MNKD) announced that new data from three different studies of Afrezza® (insulin human) Inhalation Powder were released at the American Diabetes Association’s 79th Scientific Sessions, being held June 7-11, in San Francisco, California. MannKind will present a poster with initial information from its ongoing study of Safety and Pharmacokinetics of Technosphere Insulin (Afrezza) in Pediatric Patients ¹ on Monday, June 10. This study is the first step in preparation for a phase 3 safety and efficacy study.
Afrezza® is the only orally inhaled ultra rapid-acting mealtime insulin approved by ANVISA in Brazil. WESTLAKE VILLAGE, Calif. and BELO HORIZONTE, Brazil, June 03, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) and BIOMM SA (BIOM3.SA) today announced that Afrezza® (insulin human) Inhalation Powder, an ultra rapid-acting mealtime insulin to improve glycemic control in adult patients with diabetes mellitus, has been registered by the Brazilian Health Regulatory Agency (ANVISA).
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on May 16) Adverum Biotechnologies Inc (NASDAQ: ADVM )(announced ...
MannKind Corporation (MNKD) today announced that it has entered into an exclusive marketing and distribution agreement with the AMSL Diabetes division of Australasian Medical & Scientific Ltd. for the commercialization of Afrezza® (insulin human) Inhalation Powder in Australia. "We are excited to partner with AMSL Diabetes to accelerate patients’ access to Afrezza in Australia," said Michael Castagna, Chief Executive Officer of MannKind Corporation.
MannKind (MNKD) reported financial results for their first quarter ending March 31st and provided a business update. As it relates to the financials, total revenue was $17.4M, which included $5.1M in product sales and $12.4M in collaboration revenue.
The Westlake Village, California-based company said it had a loss of 8 cents per share. The results matched Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
1Q 2019 Total Revenues of $17.4 million 1Q 2019 Afrezza Net Revenue was $5.1 million; +49% vs. 1Q 2018 1Q 2019 Collaborations and Services Revenue was $12.4 million 1Q 2019 net.